* 由恒瑞医药600276.SS董事长孙飘扬之妻女控股的中国翰森制药3692.HK周五早盘一度劲升5.1%，就抗肿瘤药物HS-20110与罗氏ROG.S订立许可协议。
* 恒生香港上市生物科技指数.HSBIO盘中跌0.6%。
* 翰森制药公告称，与罗氏订立许可协议授予被许可人开发、生产及商业化HS-20110的全球独占许可（不含中国内地、香港、澳门和台湾），将获得8,000万美元首付款，并有资格根据该产品开发、注册审批和商业化进展收取最高14.5亿美元里程碑付款，以及未来潜在产品销售的分级特许权使用费。
该产品是一款在研CDH17靶向抗体–药物偶联物$(ADC)$，目前正在中国和美国开展用于治疗结直肠癌$(CRC)$及其他实体瘤的全球I期临床试验。
* 翰森制药今年迄今暴涨114.9%，同期恒生指数.HSI大幅上扬28.7%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 崔珠珠；审校 张喜良)
((zhuzhu.cui@thomsonreuters.com; +86-21-20830048;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.